Publication: Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

Information

PGS Catalog Publication (PGP) ID: PGP000032
PubMed ID: 25569441
doi: 10.1038/gim.2014.192

Publication Date: Jan. 8, 2015

Journal: Genet Med

Authors: Pashayan N, Duffy SW, Neal DE, Hamdy FC, Donovan JL, Martin RM, Harrington P, Benlloch S, Amin Al Olama A, Shah M, Kote-Jarai Z, Easton DF, Eeles R, Pharoah PD.

PGS Associated with PGP000032

External PGS Evaluated By This Study

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.
PGS Performance Metric (PPM) ID Evaluated Score PGS Catalog Sample Set (PSS) ID Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in PGS Model PGS Performance: Other Relevant Information
PPM000105 PGS000044 (PrCa66) PSS000069 Pashayan N et al. (2015) Ext. Reported Trait: aggressive prostate cancer (Gleason score ⩾7) OR (above vs. below 50th percentile of PRS): 1.56 [1.15 - 2.1]

Evaluated Samples

PGS Catalog Sample Set (PSS) ID Detailed Phenotype Description (e.g. ICD/SNOMED codes used to identify cases) Sample Numbers Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000069 Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. 4,967 individuals
[ 1,089 cases, 3,878 controls]
100.00 %% Male samples
European
(Finnish)
ERSPC